Forgot Password?
Return to Course Listing

CME: Parkinson's disease: Optimizing pharmacotherapeutic management strategies and addressing clinical challenges

ACCREDITATION EXPIRED: July 16, 2021

Activity Description / Statement of Need:

In this online CME self-learning program:

Parkinson's disease (PD), a central nervous system disease of the autonomic and basal ganglia, neocortex, and spinal cord, is thought to affect about one million people in the United States. Its etiology is thought to include a confluence of factors including age, genetic predisposition, comorbid disease states (e.g., Gaucher’s disease), and environmental factor dynamics. Present in 1% of people over age 65 and 2.5% of those older than 80, its symptoms are the direct result of dopaminergic neuronal degradation along the nigrostriatal tract and include bradykinesia, resting tremor, muscle rigidity, and gait disturbance.

Podcast available at: Apple Podcasts or wherever you get your podcasts.

Target Audience:

The following healthcare professionals: neurologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in neurology; and any other healthcare professionals with an interest in or who clinically encounter patients with PD.


This program is supported by an educational grant from Acorda and UCB.

This activity is free of charge.


Release Date: July 16, 2019 -- Expiration Date: July 16, 2021

Faculty: Jessica Lehosit, DO

Agenda

 

Faculty introduction, disclosures

Introduction content: cursory refresher and review of PD

  • Epidemiology & risk factors
  • Diagnosis: clinical
  • Clinical features, diagnostic criteria
  • Pathophysiology and disease progression
  • Patient case(s)

Treatment of PD

  • Treatment goals and guidelines
  • Impact of treatment early in the disease process
  • Present and emerging pharmacotherapy
  • Levodopa
  • Dopamine agonists
  • MAO B inhibitors
  • Amantadine
  • COMT inhibitors
  • Antioxidants
  • Neurotrophic factors
  • Alpha synuclein-targeted therapies
  • Repurposed therapies
  • Treatment-refractory disease and complications
  • Management of motor fluctuations and dyskinesia
  • Disease complications and other effects impacting quality-of-life
  • Updates in formulations and routes of administration (e.g., inhalation)
  • Other clinical pearls, including: what to do when response to therapy diminishes; recognition and treatment of non-motor symptoms
  • A distinction between disease progression and adherence to therapy
  • Barriers to care: optimizing patients’ adherence to their therapy and minimizing adverse effects
  • Patient case(s)

Summary, conclusions, and best practice recap



Learning Objectives

By the end of the session the participant will be able to:

  • Describe the pathophysiology and disease progression of PD and their impact on patient quality-of-life
  • Describe the common clinical presentation(s) of PD
  • Apply recent biomedical literature to the management of PD the primary disease, levodopa-related fluctuations in motor function and dyskinesia, and other disease complications and effects impacting quality-of-life
  • Identify the advances in the biomedical literature concerning PD and emerging treatment options
  • List challenges and barriers to care associated with treating patients with PD

Accreditation

ACCME Activity #201336470

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

 

Faculty Disclosures:

 

Dr. Jessica Lehosit, DO, Assistant Professor of Neurology, McGuire VAMC/VCU medical center, has no relevant conflicts of interest to disclose.

Disclosures of Educational Planners: Charles Turck, PharmD has no relevant conflicts of interest to disclose.

Commercial Support Disclosure: This program is supported by an educational grant from Acorda and UCB

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Alzheimer Disease and Its Complications: Best Practices, Emerging Therapies, and Barriers to Care

Chronic inflammatory demyelinating polyneuropathy (CIDP): Optimizing pharmacotherapeutic management strategies

Migraine Updates from the American Headache Society Annual Meeting (AHS 2020)

Transthyretin amyloidosis (ATTR) and its complications: Optimizing management strategies